Peer Exchange

This discussion explores how the treatment landscape for muscle-invasive bladder cancer (MIBC) is evolving with the integration of perioperative systemic therapies around radical cystectomy. The panel discusses emerging clinical trial data supporting immunotherapy- and antibody-drug conjugate-based approaches, including perioperative durvalumab plus gemcitabine-cisplatin and enfortumab vedotin plus pembrolizumab, and how these regimens are influencing treatment selection in cisplatin-eligible and cisplatin-ineligible patients. Throughout the discussion, the expert faculty examine the impact of these therapies on surgical planning, operative experience, postoperative recovery, biomarker integration, and multidisciplinary coordination of care. The panel also highlights ongoing unmet needs, future clinical trial directions, and practical considerations for safely incorporating perioperative strategies into the modern management of MIBC.

A group of panelists discuss the evolving management of metastatic castration-sensitive prostate cancer, with a focus on how patient complexity, long-term survivorship, and emerging evidence are shaping treatment intensification strategies. They will explore practical considerations that inform selection of androgen receptor pathway inhibitors, review data from both clinical trials and real-world studies, and share perspectives on optimizing tolerability and quality of life in everyday practice.

In this Peer Exchange, expert faculty will explore the evolving role of oral androgen deprivation therapy within the advanced prostate cancer treatment landscape. This discussion will bring together multidisciplinary perspectives to examine how oral ADT is selected, coordinated, and monitored across the care team.

In this Peer Exchange, expert faculty will discuss the treatment landscape of metastatic castration-sensitive prostate cancer. We will also review long-term clinical trial outcomes and share best practices to optimize management of patients with mCSPC.

In this Peer Exchange, expert faculty will focus on the evolving management of high-risk non-muscle invasive bladder cancer (NMIBC). We’ll begin by reviewing the current treatment landscape and key unmet needs within NMIBC. Then, we will examine newly reported clinical trial data and emerging therapies before exploring best practices for integrating these advances into everyday clinical management.

Expert faculty will examine the evolving treatment landscape of metastatic castration-sensitive prostate cancer (mCSPC), shaped by the introduction of multiple androgen receptor pathway inhibitors (ARPIs). While randomized clinical trials have demonstrated their efficacy, emerging real-world evidence (RWE) provides additional perspective on how these therapies perform across diverse patient populations. The discussion will focus on recent comparative analyses of overall survival with ARPI’s exploring the clinical implications of RWE, and how these insights may inform personalized treatment decisions in daily practice.

Explore the latest breakthroughs in non–muscle-invasive bladder cancer (NMIBC). Moderated by Dr. Mark Tyson II, this expert panel dives into cutting-edge immunotherapeutic strategies and clinical advances shaping the future of NMIBC care.

Experts take a deep dive into the latest advancement, exploring groundbreaking clinical trial data, real-world evidence of newly approved therapies, and ongoing research shaping the future of NMIBC, as well as addressing the practical challenges of bringing these innovations into practice.

Experts discuss challenges with the current standard of care in non–-muscle-invasive bladder cancer (NMIBC); review data and emerging treatment options for high-risk, non–-bacille Calmette-Guérin responsive NMIBC, including drug delivery systems;, and share practical considerations for the adoption of new and emerging treatment options in NMIBC.

Panelists discuss how recent advancements in diagnostic strategies and emerging combination therapies are shaping the management of metastatic castration-sensitive prostate cancer to better address patient needs and improve outcomes.

Panelists discuss how emerging PD-1 and PD-L1 inhibitors could transform the treatment landscape for non–muscle-invasive bladder cancer, highlighting the importance of a multidisciplinary approach and ongoing clinical trials for high-risk patients.

Dr Lowentritt introduces an upcoming series revolving around biomarker utilization in prostate cancer treatment.

A panel of bladder cancer specialists review clinical trial data and discuss the evolving therapeutic landscape for BCG-unresponsive non–muscle invasive bladder cancer.

A panel of experts discuss recent updates on the use of MRI/ultrasound fusion-guided biopsy in patients with prostate cancer.

A panel of experts on prostate cancer discuss the role for PSMA-PET imaging, highlighting clinical practices, recent advances, and key updates.

Following ESMO 2023, a panel of experts on bladder cancer review recent updates and discuss the evolving treatment landscape, with a focus on non–muscle invasive bladder cancer.

Michael J. Kennelly, MD, FPMRS, FACS, joined by Kevin D. Benson, MD, MS and Karyn S. Eilber, MD, leads a comprehensive Urology Times® Viewpoints discussion on patient-centric management of overactive bladder (OAB). They cover an overview of OAB, standard care treatments, device and procedural advancements, and practical considerations for patient-centric care. The session delves into diagnostic assessments, symptom presentations, impact on quality of life, guideline recommendations for treatment, and the clinical benefits and limitations of standard pharmacological treatments. The experts also discuss the role of device-based therapies like sacral neuromodulation and intravesical botulinum toxin type A, focusing on patient eligibility, clinical experiences, and managing post-procedure care. They share insights on adapting procedures to enhance patient comfort, managing expectations, and the importance of follow-up care, providing valuable advice for enhancing patient experiences in OAB management.

This Urology Times® Viewpoints video series provides a detailed exploration of non-muscle invasive bladder cancer (NMIBC), led by Dr. Sam Chang of Vanderbilt University and featuring expert panelists Dr. Gary Steinberg, Dr. Sandip Prasad, Dr. Mark Tyson, and Dr. Roger Lee filmed at Society for Urological Oncology (SUO) 2023. The series delves into the nuances of staging and grading NMIBC, emphasizing the differences between low-grade and high-grade tumors and their implications for treatment strategies. The discussion spans a range of topics including the management of high-risk and intermediate-risk NMIBC, the challenges in treating the BCG unresponsive population, and the examination of new therapeutic advances and clinical trials, such as N803, TAR 200, and Cretostimogene Grenadenorepvec, underscoring the importance of personalized care in NMIBC treatment.

A panel of urologists and radiation oncologists who specialize in treating patients with prostate cancer provide comprehensive insights on the utilization of rectal spacers and multidisciplinary care.

A panel of experts discuss recent advances and key updates on the use of PSMA-targeted PET imaging in patients with prostate cancer.

Expert panelists review the evolving roles of PSMA-targeted PET imaging and conventional imaging in patients with prostate cancer.

Reactions to the emergence of novel immunotherapy agents for treatment of bladder cancer, including increased administration in community urology practices, and recommendations for sequencing newer therapies into treatment algorithms.

Neal Shore, MD, FACS; Bobby Liaw, MD; Vivek K. Narayan, MD, MS; and Ashley E. Ross, MD, PhD, share key insights on advances in the use of androgen receptor inhibitors (ARIs) and discuss the urologist’s role in managing patients with mCSPC and nmCRPC.

Experts in treating prostate cancer highlight recent clinical data and discuss practical implications for patient care.